High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia

Shu Huey Chen, Der Cherng Liang, Hsi Che Liu

研究成果: 雜誌貢獻文章

10 引文 (Scopus)

摘要

We sought to determine the role of granulocyte colony-stimulating factor (G-CSF) as an adjunct therapy in high-dose cytarabine-containing chemotherapy (HD C/T) for children with acute leukemia. Seventeen patients, aged 9 months to 18 years old, 8 ALL and 9 AML, were treated with cytarabine (Ara-C) 1 g/m2 q12h for 8 doses with mitoxantrone, idarubicin, VP-16, or asparaginase. A total of 71 courses of HD C/T was given. G-CSF was not used in 14 courses (Group A). Prophylactic G-CSF was given in 57 courses (Group B) as 200 μg/m2/d SC started one day after the completion of HD C/T and continued until the neutrophil recovery was maintained. The incidences of sepsis per course in Group A and Group B were 35.7% (5/14) and 40.4% (23/57), respectively. While 2 patients in Group A died of sepsis or pneumonia, none in Group B died. The mortality and delay in chemotherapy were fewer in Group B (P = 0.037 and 0.0006, respectively, Fisher exact test). There was a shorter average number of days of neutrophil

原文英語
頁(從 - 到)20-23
頁數4
期刊American Journal of Hematology
58
發行號1
DOIs
出版狀態已發佈 - 五月 1998
對外發佈Yes

指紋

Cytarabine
Granulocyte Colony-Stimulating Factor
Leukemia
Drug Therapy
Sepsis
Neutrophils
Idarubicin
Asparaginase
Mitoxantrone
Etoposide
Pneumonia
Mortality
Incidence

ASJC Scopus subject areas

  • Hematology

引用此文

High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia. / Chen, Shu Huey; Liang, Der Cherng; Liu, Hsi Che.

於: American Journal of Hematology, 卷 58, 編號 1, 05.1998, p. 20-23.

研究成果: 雜誌貢獻文章

@article{64a8c0f198744d2aaddfdb15731a6467,
title = "High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia",
abstract = "We sought to determine the role of granulocyte colony-stimulating factor (G-CSF) as an adjunct therapy in high-dose cytarabine-containing chemotherapy (HD C/T) for children with acute leukemia. Seventeen patients, aged 9 months to 18 years old, 8 ALL and 9 AML, were treated with cytarabine (Ara-C) 1 g/m2 q12h for 8 doses with mitoxantrone, idarubicin, VP-16, or asparaginase. A total of 71 courses of HD C/T was given. G-CSF was not used in 14 courses (Group A). Prophylactic G-CSF was given in 57 courses (Group B) as 200 μg/m2/d SC started one day after the completion of HD C/T and continued until the neutrophil recovery was maintained. The incidences of sepsis per course in Group A and Group B were 35.7{\%} (5/14) and 40.4{\%} (23/57), respectively. While 2 patients in Group A died of sepsis or pneumonia, none in Group B died. The mortality and delay in chemotherapy were fewer in Group B (P = 0.037 and 0.0006, respectively, Fisher exact test). There was a shorter average number of days of neutrophil",
keywords = "Acute leukemia, G-CSF, HD C/T",
author = "Chen, {Shu Huey} and Liang, {Der Cherng} and Liu, {Hsi Che}",
year = "1998",
month = "5",
doi = "10.1002/(SICI)1096-8652(199805)58:1<20::AID-AJH4>3.0.CO;2-2",
language = "English",
volume = "58",
pages = "20--23",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia

AU - Chen, Shu Huey

AU - Liang, Der Cherng

AU - Liu, Hsi Che

PY - 1998/5

Y1 - 1998/5

N2 - We sought to determine the role of granulocyte colony-stimulating factor (G-CSF) as an adjunct therapy in high-dose cytarabine-containing chemotherapy (HD C/T) for children with acute leukemia. Seventeen patients, aged 9 months to 18 years old, 8 ALL and 9 AML, were treated with cytarabine (Ara-C) 1 g/m2 q12h for 8 doses with mitoxantrone, idarubicin, VP-16, or asparaginase. A total of 71 courses of HD C/T was given. G-CSF was not used in 14 courses (Group A). Prophylactic G-CSF was given in 57 courses (Group B) as 200 μg/m2/d SC started one day after the completion of HD C/T and continued until the neutrophil recovery was maintained. The incidences of sepsis per course in Group A and Group B were 35.7% (5/14) and 40.4% (23/57), respectively. While 2 patients in Group A died of sepsis or pneumonia, none in Group B died. The mortality and delay in chemotherapy were fewer in Group B (P = 0.037 and 0.0006, respectively, Fisher exact test). There was a shorter average number of days of neutrophil

AB - We sought to determine the role of granulocyte colony-stimulating factor (G-CSF) as an adjunct therapy in high-dose cytarabine-containing chemotherapy (HD C/T) for children with acute leukemia. Seventeen patients, aged 9 months to 18 years old, 8 ALL and 9 AML, were treated with cytarabine (Ara-C) 1 g/m2 q12h for 8 doses with mitoxantrone, idarubicin, VP-16, or asparaginase. A total of 71 courses of HD C/T was given. G-CSF was not used in 14 courses (Group A). Prophylactic G-CSF was given in 57 courses (Group B) as 200 μg/m2/d SC started one day after the completion of HD C/T and continued until the neutrophil recovery was maintained. The incidences of sepsis per course in Group A and Group B were 35.7% (5/14) and 40.4% (23/57), respectively. While 2 patients in Group A died of sepsis or pneumonia, none in Group B died. The mortality and delay in chemotherapy were fewer in Group B (P = 0.037 and 0.0006, respectively, Fisher exact test). There was a shorter average number of days of neutrophil

KW - Acute leukemia

KW - G-CSF

KW - HD C/T

UR - http://www.scopus.com/inward/record.url?scp=0031901114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031901114&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8652(199805)58:1<20::AID-AJH4>3.0.CO;2-2

DO - 10.1002/(SICI)1096-8652(199805)58:1<20::AID-AJH4>3.0.CO;2-2

M3 - Article

C2 - 9590144

AN - SCOPUS:0031901114

VL - 58

SP - 20

EP - 23

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -